IRIS
BALLABENI, Vigilio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.304
AS - Asia 8.049
EU - Europa 6.822
SA - Sud America 1.075
AF - Africa 430
Continente sconosciuto - Info sul continente non disponibili 25
OC - Oceania 7
Totale 29.712
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.989
SG - Singapore 2.760
CN - Cina 2.437
VN - Vietnam 1.268
FI - Finlandia 1.264
SE - Svezia 1.060
IE - Irlanda 940
BR - Brasile 848
IT - Italia 812
DE - Germania 783
UA - Ucraina 707
HK - Hong Kong 560
FR - Francia 285
ZA - Sudafrica 267
GB - Regno Unito 259
TR - Turchia 245
BD - Bangladesh 234
NL - Olanda 232
CA - Canada 196
RU - Federazione Russa 122
IN - India 117
AR - Argentina 85
BE - Belgio 69
MX - Messico 61
CI - Costa d'Avorio 57
AT - Austria 56
ES - Italia 53
IQ - Iraq 51
ID - Indonesia 46
RO - Romania 46
JP - Giappone 45
PH - Filippine 41
KR - Corea 37
EC - Ecuador 36
PK - Pakistan 36
TH - Thailandia 36
CZ - Repubblica Ceca 35
PL - Polonia 29
CM - Camerun 25
CO - Colombia 25
EU - Europa 24
VE - Venezuela 21
MA - Marocco 20
PY - Paraguay 19
TW - Taiwan 16
UZ - Uzbekistan 16
MY - Malesia 14
EG - Egitto 13
LT - Lituania 13
PA - Panama 13
AZ - Azerbaigian 12
CL - Cile 12
PE - Perù 11
TN - Tunisia 11
CR - Costa Rica 10
JM - Giamaica 9
DO - Repubblica Dominicana 8
ET - Etiopia 8
LB - Libano 8
NP - Nepal 8
UY - Uruguay 8
BO - Bolivia 7
KZ - Kazakistan 7
SA - Arabia Saudita 7
SI - Slovenia 7
AE - Emirati Arabi Uniti 6
AU - Australia 6
BG - Bulgaria 6
DZ - Algeria 6
IR - Iran 6
JO - Giordania 6
KE - Kenya 6
AL - Albania 5
EE - Estonia 5
PT - Portogallo 5
SY - Repubblica araba siriana 5
DK - Danimarca 4
HU - Ungheria 4
IL - Israele 4
NI - Nicaragua 4
OM - Oman 4
SC - Seychelles 4
SN - Senegal 4
TT - Trinidad e Tobago 4
BY - Bielorussia 3
HN - Honduras 3
HR - Croazia 3
MD - Moldavia 3
RS - Serbia 3
SV - El Salvador 3
BB - Barbados 2
BN - Brunei Darussalam 2
CH - Svizzera 2
CY - Cipro 2
GA - Gabon 2
GE - Georgia 2
GY - Guiana 2
KG - Kirghizistan 2
LY - Libia 2
NG - Nigeria 2
Totale 29.688
Salva come PNG Salva come JPEG
Città #
Dallas 4.214
Singapore 1.455
Ashburn 1.011
Dublin 939
Chandler 911
San Jose 791
Jacksonville 746
Santa Clara 607
Beijing 569
Hong Kong 534
Dearborn 450
Ann Arbor 448
Ho Chi Minh City 409
Boardman 327
Hanoi 270
Johannesburg 255
Nanjing 246
New York 238
Los Angeles 206
Izmir 197
Parma 193
Munich 183
Princeton 179
Shanghai 170
Lauterbourg 166
San Mateo 132
Wilmington 127
Hefei 124
Toronto 117
Helsinki 105
Bremen 88
Buffalo 87
Hebei 83
Kunming 78
Jinan 75
Nanchang 75
Shenyang 75
São Paulo 71
Moscow 70
Brussels 66
Grafing 64
Frankfurt am Main 60
Abidjan 57
Woodbridge 55
Chicago 54
Guangzhou 54
Haiphong 52
Tianjin 52
Turku 51
Vienna 48
Des Moines 45
Changsha 44
Da Nang 44
Columbus 43
Council Bluffs 42
London 39
Tokyo 38
Seattle 34
Brooklyn 32
Milan 31
Montreal 31
Rio de Janeiro 30
Bologna 27
Fremont 27
Jiaxing 27
Auburn Hills 24
Warsaw 24
Atlanta 23
Norwalk 23
The Dalles 23
Hangzhou 22
Houston 22
Pune 22
Denver 20
Marseille 20
Zhengzhou 20
Amsterdam 19
West Jordan 19
Belo Horizonte 18
Biên Hòa 18
Jakarta 18
Orem 18
Stockholm 18
Bengaluru 17
Boston 17
Brno 17
Lubbock 17
Ninh Bình 17
Phoenix 17
Redondo Beach 17
Baghdad 16
Bangkok 16
Brasília 16
Chennai 16
Manchester 16
San Francisco 16
Hải Dương 15
Mexico City 15
Nuremberg 15
Rome 15
Totale 18.814
Salva come PNG Salva come JPEG
Nome #
1,8-Naphthyridines IX. Potent anti-inflammatory and/or analgesic activity of a new group of substituted 5 amino[1,2,4]triazolo[4,3-a] [1,8]naphthyridine-6 carboxamides, of some their Mannich base derivatives and of one novel substituted 5-amino-10-oxo-10Hpyrimido[1,2-a [1,8]naphthyridine-6-carboxamide derivative 1.699
1,5-Benzodiazepines Part XIII. Substututed 4H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepin-5-amines and 4H-imidazo-[1,2-a][ 1,5]benzodiazepin-5-amines as analgesic, anti-inflammatory and/or antipyretic agents with low acute toxicity 1.674
1,5-Benzodiazepin tricyclic derivatives as analgersic, anti-inflammatory and /or antipyretic agents with very low acute gastrolesivity and toxicity 1.619
1,8-Naphthyridines V. Novel N-substituted 5-amino-N,N-diethyl-9-isopropyl [1,2,4]triazolo[4,3-a] [1,8]naphthyridine-6-carboxamides, as potent anti-inflammatory and/or analgesic agents completely devoid of acute gastrolesivity 252
Pharmacological characterization of second generation FXR agonists as effective EphA2 antagonists: A successful application of target hopping approach 251
2-Aminobenzimidazoles as new potent H3-antagonists 224
Pharmacological evaluation of new bioavailable small molecules targeting Eph/ephrin interaction 223
Antiplatelet and antithrombotic activities of essential oil from wild Ocotea quixos (Lam.) Kosterm. (Lauraceae) calices from Amazonian Ecuador 219
Optimization of EphA2 antagonists based on a lithocholic acid core led to the identification of UniPR505, a new 3α-carbamoyloxy derivative with antiangiogenetic properties 217
A promising imidazole-free histamine H3 receptor antagonist with good brain penetration and anticholinesterase activity. 213
Dibasic biphenyl H(3) receptor antagonists: Steric tolerance for a lipophilic side chain. 208
Enteric dysfunctions in experimental Parkinson's disease: alterations of excitatory cholinergic neurotransmission regulating colonic motility in rats 206
Antinociceptive and gastroprotective effects of inhaled and orally administered Lavandula hybrida Reverchon “Grosso” essential oil 203
Analgesic properties of benzisothiazole/ benzimidazole derivatives with acidic groups 199
Synthesis, biological activity, QSAR and QSPR study of 2/aminobenzimidazole derivatives as potent H3-antagonists 198
Aminobenzimidazoles as new potent H3-antagonists 196
Protective Effects of a Protease Inhibitor (Gabexate Mesilate) on Intestinal Ischemia/Reperfusion Injury in Rats 194
1,8-Naphthyridines VII. New substituted 5-amino[1,2,4]triazolo[4,3-a][1,8]naphthyridine-6-carboxamides and their isosteric analogues, exhibiting notable anti-inflammatory and/or analgesic activities, but no acute gastrolesivity. 193
1,8-Naphthyridines VIII. Novel 5-aminoimidazo[1,2-a] [1,8]naphthyridine-6-carboxamide and 5-amino[1,2,4]triazolo[4,3-a] [1,8]naphthyridine-6-carboxamide derivatives showing potent analgesic or anti-inflammatory activity, respectively, and completely devoid of acute gastrolesivity. 192
Accommodation and peristalsis are functional responses to chronic obstruction in rat hypertrophic ileum 190
2,4-Substituted benzopyrano[4,3-d]pyrimidines and benzopyrano[4,3-d]pyrimidin-5-ones: synthesis and antiplatelet activity 189
Impact of S1P mimetics on mesenteric ischemia/reperfusion injury 186
2-Amino-1,2-benzisothiazolin-3-one derivatives as powerful antiplatelet agents 185
The Role of HB-Donor Groups in the Heterocyclic Polar Fragment of H3-Antagonists. I. Synthesis and Biological Assays 183
Caratterizzazione farmacologica in vitro di nuovi agonisti muscarinici analoghi dell'Oxotremorina 179
Cognition enhancing effect in rats of a selected histamine H3 receptor antagonist with good brain penetration 178
NEW EPH ANTAGONISTS DISCRIMINATING BETWEEN EPH-AS AND EPH-BS CLASSES 177
Validation of a histamine H3 receptor model through structure–activity relationships for classical H3 antagonists 177
Access to CNS of selected H3-antagonists: ex vivo binding study in rats 177
Suppression of inflammatory events associated to intestinal ischemia-reperfusion by 5-HT1A blockade in mice 176
Gastrointestinal symptoms and local oxidative stress in a model of Parkinson's Disease in rats 176
Daily assumption of fermented milk containing Bifidobacterium breve 246 B® promotes prophylactic effects against intestinal inflammation in mice 175
Adaptive changes in rat ileum motility induced by mild mesenteric ischemia/reperfusion injury: role of endogenous mediators and reperfusion time 170
Accommodation and peristalsis are functional responses to obstruction in rat hypertrophic ileum 168
Histamine H4 receptor antagonism and mesenteric ischemia/reperfusion injury in mice 167
Analgesici-antipiretici benzopirano pirimidinici non acidici attivi per via orale privi di gastrolesività 167
Probing the effects of MR120 in preclinical chronic colitis: A first-in-class anti-IBD agent targeting the CCL20/CCR6 axis 166
A New Potent and Selective Histamine H3-Receptor Antagonist, 4(5)-{2-[4(5)-cyclohexylimidazol-2-ylthio]ethyl}imidazole 165
1-Methyl and 1-(2-hydroxyalkyl)-5-(3-alkyl/cycloalkyl/phenyl/naphthylureido)-1H-pyrazole-4-carboxylic acid ethyl esters as potent human neutrophil chemotaxis inhibitors 165
Dual-Acting Drugs: an in vitro Study of Nonimidazole Histamine H(3) Receptor Antagonists Combining Anticholinesterase Activity 164
2-Amino-1,2-benzisothiazolin-3-one Derivatives: Synthesis and Assessment of their Antiplatelet/Spasmolytic Effects 163
Dibasic non-imidazole histamine H3 receptor antagonists with a rigid byphenyl scaffold. 162
5-HT1A receptors as target to protect the intestine in an experimental model of colitis 162
Intestinal chronic obstruction affects motor responsiveness of rat hypertrophic longitudinal and circular muscles 162
Discovery of small-molecule targeting the CCL20/CCR6 axis as first-in-class inhibitors for inflammatory bowel diseases 161
Comparative screening of plant essential oils: phenylpropanoid moiety as basic core for antiplatelet activity 161
Multiple approaches for the discovery and development of small molecules targeting Eph-ephrin protein-protein interaction 161
QSAR study of 2-aminobenzimidazole derivatives as H3 antagonists 159
Anomalous responses to histamine stimulation of guinea-pig oesophageal muscularis mucosae. 158
5-Alkoxy-2-hydrazino and 5-methoxy-2-amino-5H[1]benzopyrano[4,3-d]pyrimidines: synthesis and pharmacological activity 157
Access to CNS of selected H3-antagonists: ex vivo binding study in rats 156
Motor responses of rat hypertrophic intestine following chronic obstruction 155
Radiological analysis of gastrointestinal dysmotility in a model of central nervous dopaminergic degeneration: Comparative study with conventional in vivo techniques in the rat 155
Intestinal Hypoxia and reperfusion: role for Eph-ephrin system 155
Anomalous responses to histamine stimulation of guinea-pig oesophageal muscularis mucosae 152
Nuovi potenti agonisti muscarinici oxotremorina-M simili a struttura acetilenica: studio funzionale in vitro 152
Development and validation of a LC-MS method with electrospray ionization for the determination of the imidazole H(3) antagonist ROS203 in rat plasma. 151
Regional differences in motor responsiveness to antimuscarinic drugs in rabbit isolated small and large intestine 150
Role of 5-HT in intestinal ischemia-reperfusion: suppression of inflammatory events by 5-HT1A blockade in mice 150
Influence of Nitric Oxide system in mesenteric ischemia-reperfusion induced injury in mice 150
Influence of adenosine in the systemic and local injury caused by mesenteric ischemia-reperfusion in mice 150
Alterations of intestinal motor responsiveness in a model of mild mesenteric ischemia/reperfusion in rats 150
Novel antiplatelet and antithrombotic activities of essential oil from Lavandula hybrida Reverchon "Grosso" 149
Assessment of intestinal motor responsiveness in an ischemia/reperfusion model in rats 149
PHARMACOLOGICAL CHARACTERIZATION OF NEW COMPOUNDS AIMED AT INHIBITING EPH-EPHRIN INTERACTION IN GLIOBLASTOMA 148
Brain Pharmacokinetics of Non-Imidazole Biphenyl H3 Receptor Antagonists: a Liquid Chromatography/Electrospray-Mass Spectrometry and ex vivo Binding Study in Rats 148
Assessment of intestinal motor responsiveness in an ischemia/reperfusion model in rats 147
Preventive effect of 5-HT1A receptor agonist Buspirone on mesenteric ischemia/reperfusion-induced inflammatory injuries in mice 147
CNS access of selected H3-antagonists: ex vivo binding study in rats 144
Functional Studies of New Imidazole H3-Antagonists on Guinea-Pig Isolated Preparations 144
Distinct Roles of α4β2 and α7 Nicotinic Receptors in the Modulation of Inflammatory Responses in TNBS-Induced Colitis 143
Synthesis of new 5,6-dihydrobenzo[h]quinazoline 2,4-diamino substituted and antiplatelet/antiphlogistic activities evaluation. 142
The selective inhibition of inducible nitric oxide synthase prevents intestinal ischemia-reperfusion injury in mice 141
In vitro and in vivo pharmacological analysis of imidazole-free histamine H3 receptor antagonists: promising results for a brain-penetrating H3 blocker with weak anticholinesterase activity. 141
Preliminary study of calcium balance and bone mineralization improvement by a new calcium supplement in growing rats 141
Bis(ammonio)alkane-type agonists of muscarinic acetylcholine receptors: synthesis, in vitro functional characterization, and in vivo evaluation of their analgesic activity 140
Different role of the Histamine H3 Receptor in Vagal-, Betanechol-, Pentagastrin-induced Gastric Acid Secretion in Anaesthetized Rats 139
2-Amino/azido/hydrazino-5-alkoxy-5H-[1]benzopyrano[4,3-d]pyrimidines: synthesis and pharmacological evaluation 139
Synthesis and biological evaluation of new non-imidazole H(3)-receptor antagonists of the 2-aminobenzimidazole series 138
Synthesis and biological assays of new H3-antagonists with imidazole and imidazoline polar groups 137
Discovery of histamine H3 receptor antagonistic property of simple imidazole-free derivatives: preliminary pharmacological investigation. 137
Radiological analysis of gastrointestinal dysmotility associated with central dopaminergic impairment in an animal model of parkinson's disease (PD) 135
R-a-methylhistamine-induced inhibition of gastric acid secretion in pylorus-ligated rats via central histamine H3 receptors 134
Proteinase-Activated Receptor 2 agonist prevents mesenteric ischemia/reperfusion injury in rats: partila involvement of Substance P (SP) and Calcitonin-Gene Related Peptide (CGRP) 133
RESPONSIVENESS OF LONGITUDINAL AND CIRCULAR MUSCLE TO RELAXING MEDIATORS IS DIFFERENTIALLY AFFECTED IN RAT HYPERTROPHIED ILEUM 133
Disruption of Eph-ephrin B signaling pathways mitigates inflammation in a murine model of Crohn’s disease 133
Role of Glutamate- N-methyl-D-Aspartate (NMDA) Receptors in Neuronal Plasticity and Gastrointestinal Transit Delay Induced by Ischemia/Reperfusion in Rats 132
Protection by the EPH-EPHRIN System Against Mesenteric Ischemia-Reperfusion Injury 132
Evidence for the involvement of 5-HT(2A) receptors in mild mesenteric ischemia/reperfusion dysfunctions in mice 131
Synthesis and pharmacological screening of novel non-acidic gastric-sparing antiinflammatory/antiplatelet agents:5-alkyl/cycloalkylamino substituted 2-amino-5H-[1]benzopyrano[4,3-d]pyrimidines 131
Histamine H3-antagonists: the basicity of the polar group in quantitative structure-activity and structure-property relationship 130
Synthesis and structure-activity relationships for biphenyl H3 receptor antagonists with moderate anti-cholinesterase activity. 129
Pharmacological screening of novel antiplatelet agents with analgesic activity 129
Mesenteric ischemia-reperfusion: an overview of preclinical drug strategies 128
Antinflammatory properties of novel 5-amino[1,2,4]-triazolo[4,3-a][1,8]naphthyridines-caroboxamides derivatives 127
Functional comparison between nuvenzepine and pirenzepine on different guinea pig isolated smooth muscle preparations 127
Synthesis and Biological Evaluation of N-Pyrazolyl-N'-alkyl/benzyl/phenylureas: a New Class of Potent Inhibitors of Interleukin 8-Induced Neutrophil Chemotaxis 126
Screening di nuovi agenti antiinfiammatori/antiaggreganti non-acidici: sviluppo di 2-amino-5H-[1]benzopirano[4,3-d]pirimidine 5-alchil/cicloalchilamino sostituite prive di attivita' gastrolesiva 126
Synthesis and functional characterization of novel heterocyclic derivatives related to oxotremorine and oxotremorine-M 125
Progress in 5H [1] benzopyrano[4,3-d]pyrimidin-5-amine series: “-methoxy derivatives effective as antiìplatelet agents with analgesic activity 124
Totale 20.671
Salva come PNG Salva come JPEG
Categoria #
all - tutte 89.626
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 89.626
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202137 0 0 0 0 0 0 0 0 0 0 0 37
2021/20221.034 24 30 25 111 62 85 121 136 41 65 77 257
2022/20233.734 445 375 229 259 385 411 71 213 1.124 40 121 61
2023/20241.332 81 106 45 52 106 348 115 67 49 74 95 194
2024/20254.199 122 227 295 225 367 499 144 182 468 412 362 896
2025/202613.035 880 1.680 3.915 958 1.250 546 977 302 1.294 690 339 204
Totale 29.849